New Delhi [India], September 17 (ANI): Hoping to strengthen India's position as a global vaccine and biologics manufacturing powerhouse, COVID-19 vaccine Covishield maker Serum Institute of India (SII) announced a strategic alliance with biopharmaceutical company Biocon Biologics Limited (BBL).
Bengaluru (Karnataka) [India], September 17 (ANI): Biocon Biologics Limited (BBL), a subsidiary of Biocon Ltd. and Serum Institute Life Sciences Private Limited (SILS) announced a strategic alliance on Thursday and BBL said it will offer around 15 per cent stake to SILS at a post-money valuation of about USD 4.9 billion.
\
\
\
\
